A Long-term Follow-up Study to Evaluate the Safety and Effectivity of AL-001 Ophthalmic Injection in Subjects with Wet Age-related Mecular Degeneration (wAMD)
Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY
This study is designed to evaluate long-term safety and efficacy of AL-001 ophthalmic injection following suprachoroidal space(SCS) administration in subjects with wAMD. Eligible patients, are those who were previously enrolled in a clinical study in which they received a single dose of AL-001 administered via suprachoroidal space injection.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 50
Healthy Volunteers: f
View:
• The subjects enrolled in AL-001 study and received AL-001 ophthalmic injection.
• The subject or their legal representative agrees to participate in this study and signs a written ICF.
• The subjects are willing and able to follow planned visits and procedures.
Locations
Other Locations
China
Chinese Academy of Medical Sciences & Peking Union Hospital
RECRUITING
Beijing
Contact Information
Primary
AnlongBio
info@anlongbio.com
+86-010-80414166
Time Frame
Start Date: 2024-12-09
Estimated Completion Date: 2029-06-30
Participants
Target number of participants: 21
Treatments
The subjects received AL-001 ophthalmic injection
Evaluate long-term safety and efficacy
Related Therapeutic Areas
Sponsors
Leads: Beijing Anlong Biopharmaceutical Co., Ltd.